A Multicenter Prospective Cohort Study Study of CLAG Regimen in Acute Myeloid Leukemia Patients With First-induction Failure

Not yet recruiting

• Conditions: AML
• Interventions: Combination Product: CLAG

• Registration Number: NCT05875649
• Lead Sponsor: Nanfang Hospital, Southern Medical University

Brief Summary

Most of patients with acute myeloid leukemia achieved complete remission (CR) after primary induction chemotherapy, there were 20-30% patients without CR after first-induction. It was uncertain how to treat these patients. It was investigated in our study that these patients were re-induced with CLAG Regimen. The CR ratio, overall survival (OS) and relapsed-free survival (RFS) was statistically analysed in these patients.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2023-05-16
• Study First Submitted QC: 2023-05-16
• Study First Posted: 2023-05-25
• Status Verified: 2023-07
• Study Start: 2023-07-02
• Last Update Submitted: 2023-07-02
• Last Update Posted: 2023-07-05
• Primary Completion: 2027-08-20
• Study Completion: 2027-12-20

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 137

Inclusion Criteria

• Acute myeloid leukemia patients with first-induction failure

Exclusion Criteria

• Acute myeloid leukemia patients with serious infection and organ dysfunction.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Group	CLAG	Acute myeloid leukemia patients with first-induction failure

Primary Outcome Measures

Name	Time	Method
Study of CLAG Regimen in Acute Myeloid Leukemia Patients With First-induction failure	6 months	CLAG Regimen improves CR rate in acute myeloid leukemia patients with first-induction failure

Trial Locations

Locations (1)

Nanfang Hospital of Southern Medical University; 🇨🇳 Guanzhou, Guangdong, China